Evidence map›Paper›PMID 41654231›Full record

ArticleToxicology and applied pharmacology2026

The effects of tungsten inhalation and continuous administration of angiotensin II on cardiac injury and pulmonary outcomes.

Milad MazloumiBakhshayesh, Russell P Hunter, Brenna Baird, Rui Liu, Anahi Gabriela Jimenez-Campos, Siem Goitom, Edward B Barr, Guy W Herbert, Selita N Lucas, Charlotte M McVeigh and 5 more

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Milad MazloumiBakhshayeshDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Russell P HunterDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Brenna BairdDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Rui LiuDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Anahi Gabriela Jimenez-CamposDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Siem GoitomDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Edward B BarrDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Guy W HerbertDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Selita N LucasDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Charlotte M McVeighDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Jorge MorenoDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Yiliang ZhuDepartment of Internal Medicine, The University of New Mexico, School of Medicine, Albuquerque, NM 87131, United States of America.
Barry E BleskeDepartment of Pharmacy Practice and Administrative Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Matthew J CampenDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America.
Alicia M BoltDepartment of Pharmaceutical Sciences, The University of New Mexico, College of Pharmacy, Albuquerque, NM 87131, United States of America. Electronic address: ambolt@salud.unm.edu.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
University of New Mexico Center for Metals in Biology and Medicine - equipment supplementP20GM130422 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Priscilla Marie De La Cruz · 2020 to 2026
$20.4M
UNM Metals Exposure and Toxicity Assessment on tribal Lands in the Southwest (METALS) Superfund Research ProgramP42ES025589 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUDSON, LAURIE G · 2017 to 2025
$16.4M
Mechanisms of Vascular Toxicity from Inhaled ToxicantsR01ES014639 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J · 2008 to 2023
$6.7M
Pilot Project CoreP30ES032755 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI FENG, CHANGJIAN (JIM) · 2022 to 2025
$5.2M
Influence of Dietary Lipids on Gestational Outcomes of Ozone ExposureF31HD107945 · NICHD · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUNTER, RUSSELL · 2022 to 2023
$58k
NCI NIH HHS P30 CA118100NICHD NIH HHS F31 HD107945NIEHS NIH HHS P30 ES032755NIEHS NIH HHS P42 ES025589NIEHS NIH HHS R01 ES014639NIGMS NIH HHS P20 GM130422NIOSH CDC HHS R21 OH012552
6 · The paper itself

Abstract

Tungsten exposure is associated with multiple cardiovascular diseases, but limited information exists on the mechanistic underpinnings of these relationships. The current study investigated the individual and combined effects of angiotensin II (AT-II) treatment, as a model of accelerated cardiovascular disease risk, and tungsten (W) exposure on cardiac function, to provide insights into potential mechanisms involved in tungsten-mediated cardiac injury. Mice received AT-II (0.73 mg/kg/d) or saline (Veh) for 24 days through osmotic mini-pumps. The final 2-weeks of treatment, mice were exposed 4 times (4 h each) to filtered air (FA) or 1.50 ± 0.22 mg/m

Indexed as

Angiotensin IILungTungstenAdministration, InhalationAnimalsInhalation ExposureMaleMiceMice, Inbred C57BLTroponin IAngiotensin IITroponin ITungstenAngiotensin IICardiac InjuryCardiac Troponin IInhalationParticulate MatterTungsten

Identifiers

PMID41654231
PMCPMC12956142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.